Sinopharm Capital
47
43M
44
3.92
11
0.06
3
- Areas of investment
Summary
Sinopharm Capital is the famous VC, which was founded in 2012. The venture was found in Asia in China. The main department of described VC is located in the Shanghai.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 investment rounds annually. The real fund results show that this VC is 51 percentage points more often commits exit comparing to other companies. The high activity for fund was in 2018.
For fund there is a match between the location of its establishment and the land of its numerous investments - China. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Ansun BioPharma, Dingdang Kuaiyao, HealthCare Biotech. Among the most popular fund investment industries, there are Health Care, Pharmaceutical. The fund has no exact preference in a number of founders of portfolio startups.
The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Sinopharm Capital, startups are often financed by ZhenFund, Sequoia Capital China, PrairieGold Venture Partners. The meaningful sponsors for the fund in investment in the same round are TF Capital, Lilly Asia Ventures, YuanMing Capital. In the next rounds fund is usually obtained by Lilly Asia Ventures, TF Capital, Qiming Venture Partners.
Investments analytics
Analytics
- Total investments
- 47
- Lead investments
- 11
- Exits
- 3
- Rounds per year
- 3.92
- Follow on index
- 0.06
- Investments by industry
- Health Care (29)
- Biotechnology (16)
- Medical (12)
- Pharmaceutical (9)
- Medical Device (5) Show 30 more
- Investments by region
-
- China (39)
- United States (5)
- Singapore (1)
- Canada (1)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 10
- Avg. valuation at time of investment
- 27M
- Group Appearance index
- 0.77
- Avg. company exit year
- 8
- Avg. multiplicator
- 6.91
- Strategy success index
- 0.40
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| GenFleet Therapeutics | 08 Mar 2020 | Biotechnology, Health Care, Pharmaceutical | Early Stage Venture | 61M | Shanghai, China |
| Huiyi Huiying | 16 Nov 2020 | Artificial Intelligence, Health Care, Hospital, Big Data, Medical Device, Medical, Cloud Computing | Late Stage Venture | 15M | Beijing, Dongcheng District, China |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.